Scandinavia, Accelerator, Innovation, 2018

Kontigo Care reaching the international market

10th July 2019

The Swedish e-health company will support European citizens in reaching long lasting sobriety

Kontigo Care is enrolled in the EIT Health Product Market Fit programme, accelerating the outreach to European citizens with their innovative digital services by ensuring sustainable sobriety in alcohol and gambling dependent patients. Kontigo Care is already a very successful company, saving lives of Swedish patients with alcohol-dependence problems and supporting their relatives as well.


Kontigo Care has developed a disruptive medical device (pictured) that through advanced AI and behaviour analysis which can identify relapse, create personalised care and positive behavioural patterns for alcohol and gambling dependent patients, thereby enhancing any therapy method used by alcohol care providers.

The unique platform called “Previct” allows caregivers and patients to predict and prevent relapse behaviours. In the long run, it helps measure evidence-based outcome of treatments and will therefore help to lower society healthcare costs related to alcohol behaviours.


“Kontigo Care is all about collaboration”, says Kontigo Care ‘s CEO, Henrik Nordlindh (pictured). The device was supported by the Uppsala County council, and tested by the Uppsala Municipality – both EIT Health Scandinavia’s Partners.

“We see EIT Health as a great opportunity to support the development of future Healthcare for European citizens.” says Henrik Nordlindh.

Christos Vaitsis, EIT Health Scandinavia Business Creation Manager, guided Kontigo Care towards the Product Market Fit programme, because it was adapted to accelerate outreach to their unique services outside Swedish borders.

We look forward to following Kontigo Care’s journey in the European arena!

Click here to learn more about the Product/Market Fit programme.

Learn more about Kontigo Care. joins forces with La Roche-Posay joins forces with La Roche-Posay

Discover how the partnership will benefit patients

Find out more

Leuko closes €5M Series A round

Leuko closes €5M Series A round

Learn more about Leuko and its achievements

Find out more

EIT Health appoints three new Supervisory Board members

EIT Health appoints three new Supervisory Board members

Join us in welcoming our new Board members

Find out more